Zenas BioPharma, Inc.
ZBIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Zenas BioPharma, Inc. (ZBIO) is listed under Biotechnology. Valued at $1.75B, ZBIO is a small-cap name in its sector. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Market Cap
$1.75B
Beta
-0.88
P/E (TTM)
—
P/E (Fwd)
-5.77
EPS (TTM)
$-9.63
EPS (Fwd)
$-4.66
ROE
-199.0%
ROA
-34.4%
Cash
$643.1M
Total Debt
$297.9M
Free CF
-$211.4M
52W Change
-15.5%
Annual Financials
Cash vs Debt
Where ZBIO stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, ZBIO finished 1.43% below its 150-day moving average ($25.20) and 0.81% above its 200-day moving average ($24.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ZBIO overbought or oversold?
At the October 19, 2026 close, ZBIO's RSI(14) was 38.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $643.1M in cash comfortably exceeding the $297.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$211.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -199.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Zenas BioPharma, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Zenas BioPharma, Inc.'s trajectory.